-
07:48:07 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

APLIF Stock News

11/19/21 7:42 AM
OTC : APLIF
managementclinical trial
Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced positive one year challenge results from its preclinical study evaluating the efficacy of biodefense vaccine candidate ATI-1701 in a lethal model of tularemia. Both 28- and 90- day efficacy data have also been presented...
RHEA-AI
neutral
11/12/21 5:41 PM
OTC : APLIF
earnings
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer
Appili Therapeutics Inc., a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2022, which ended on September 30, 2021. “Although the top-line results of our Phase 3 PRESECO trial were not what we had hoped for, I am incredibly proud of all that...
RHEA-AI
neutral
11/12/21 7:19 AM
OTC : APLIF
clinical trial
Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced that the Phase 3 PRESECO clinical trial evaluating oral antiviral Avigan ®/ Reeqonus™ for the treatment of mild-to-moderate COVID-19 did not achieve statistical significance on the primary endpoint of time to sustained clinical...
RHEA-AI
neutral
09/23/21 7:48 AM
OTC : APLIF
clinical trialcovid-19
Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus™ for the Treatment of Mild-to-Moderate COVID-19
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced it has completed enrollment in its global Phase 3 PRESECO trial evaluating oral Avigan ®/ Reeqonus™ as a potential COVID-19 treatment. With today’ s announcement, the double-blind, placebo-controlled, randomized, global,...
RHEA-AI
neutral
09/20/21 7:44 AM
OTC : APLIF
clinical trialcovid-19
Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus™ for COVID-19 Patients
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced it entered into an agreement with FUJIFILM Toyama Chemical Co., Ltd., that will provide funding support for its Phase 3 PRESECO clinical trial. As part of the agreement, FFTC will receive direct access to PRESECO data in support of local...
RHEA-AI
neutral
09/17/21 7:17 AM
OTC : APLIF
covid-19
Appili Therapeutics Announces Completion of Patient Enrollment for Avigan®/Reeqonus™ Viral Shedding Sub- Study for Mild-to-Moderate COVID-19 Patients
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced it has completed patient enrollment in the viral shedding sub-study portion of its Phase 3 PRESECO trial evaluating Avigan ®/ Reeqonus™ as a potential oral antiviral COVID-19 treatment in the United States. The viral shedding...
RHEA-AI
neutral